On Jan. 11, the FDA said it has not found a causal link between glucagon-like peptide-1 receptor agonists, such as Ozempic and Mounjaro, and suicidal thoughts.
Read the full post on Becker's Hospital Review - Healthcare News
GLP-1s not linked to suicidal thoughts: Early FDA review
